Cargando…

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Januszewski, Andrzej S., Chen, David, Scott, Russell S., O’Connell, Rachel L., Aryal, Nanda R., Sullivan, David R., Watts, Gerald F., Taskinen, Marja-Riitta, Barter, Philip J., Best, James D., Simes, R. John, Keech, Anthony C., Jenkins, Alicia J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455555/ https://www.ncbi.nlm.nih.gov/pubmed/34548531 http://dx.doi.org/10.1038/s41598-021-98064-y

Ejemplares similares

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
por: Scott, Russell, et al.
Publicado: (2009)

The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study
por: Ong, Kwok-Leung, et al.
Publicado: (2021)

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study
por: Ting, Ru-Dee, et al.
Publicado: (2012)

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
por: Forsblom, Carol, et al.
Publicado: (2010)

Correction: A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
por: Simes, John, et al.
Publicado: (2010)

A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
por: Simes, John, et al.
Publicado: (2010)

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy
por: Yetukuri, Laxman, et al.
Publicado: (2011)

An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
por: Noonan, Jonathan E., et al.
Publicado: (2013)

Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort
por: Best, James D., et al.
Publicado: (2012)

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial
por: Scott, Russell, et al.
Publicado: (2011)

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
por: Rajamani, Kushwin, et al.
Publicado: (2009)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice
por: Finch, Emily R., et al.
Publicado: (2020)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease
por: Januszewski, Andrzej S., et al.
Publicado: (2020)

Effect of HDL composition and particle size on the resistance of HDL to the oxidation
por: Shuhei, Nakanishi, et al.
Publicado: (2010)

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
por: Adiels, Martin, et al.
Publicado: (2015)

Hydroxyaromatic Fluorophores
por: Hurley, Joseph J. M., et al.
Publicado: (2021)

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
por: Chan, Dick C., et al.
Publicado: (2009)

ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects
por: Kahri, Juhani, et al.
Publicado: (2006)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model
por: Krengel, Annette, et al.
Publicado: (2013)

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models
por: Berglund, Martin, et al.
Publicado: (2015)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Rigidochromism by imide functionalisation of an aminomaleimide fluorophore
por: Husband, Jonathan T., et al.
Publicado: (2021)

Imaging the eye and its relevance to diabetes care
por: Quinn, Nicola, et al.
Publicado: (2020)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Detecting responses to treatment with fenofibrate in pedigrees
por: Cherlin, Svetlana, et al.
Publicado: (2018)

Effect of Fenofibrate Medication on Renal Function
por: Kim, Sungjong, et al.
Publicado: (2017)

Fenofibrate-induced renal dysfunction, yes or no?
por: Emami, Fatemeh, et al.
Publicado: (2020)

The role of fenofibrate in the treatment of COVID-19
por: Yasmin, Farah, et al.
Publicado: (2021)

Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency
por: Hamilton-Craig, I., et al.
Publicado: (2012)

Hemodynamic Effects of Fenofibrate and Coenzyme Q(10) in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction
por: Chew, Gerard T., et al.
Publicado: (2008)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy
por: Fu, Dongxu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qegcdohm7ssh5r618aut6icdca